Less Ads, More Data, More Tools Register for FREE

Pin to quick picksORPH.L Regulatory News (ORPH)

  • There is currently no data for ORPH

Offer Wholly Unconditional

17 Jan 2020 07:00

RNS Number : 0961A
Open Orphan PLC
17 January 2020
 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF ANY SUCH JURISDICTION

 

17 January 2020

Recommended All Equity Offer

for

HVIVO PLC ("HVIVO")

to merge with

OPEN ORPHAN PLC ("OPEN ORPHAN")

 

 Offer Wholly Unconditional

Introduction

On 9 December 2019, the boards of Open Orphan and hVIVO announced that they had reached agreement on the terms of a recommended all-equity offer for the entire issued and to be issued share capital of hVIVO (the "Offer"). Under the terms of the Offer, hVIVO Shareholders will be entitled to receive 2.47 New Open Orphan Shares for every one hVIVO Share. The Offer represents a value of approximately 15.56 pence per hVIVO Share and a premium of 33.8 per cent. based upon the hVIVO Closing Price on 6 December 2019, being the last practicable date prior to announcement of the Offer, valuing hVIVO at approximately £12.96 million.

On 31 December 2019, Open Orphan announced that the Offer had been declared unconditional as to acceptances and on 14 January 2020 announced that it had received acceptances in respect of 77,348,100 hVIVO Shares, representing approximately 92.5 per cent. of the issued ordinary share capital of hVIVO.

Offer Wholly Unconditional

Open Orphan announces that it has decided, in accordance with the Offer Document, to waive the outstanding conditions under the Offer. Accordingly, there are no further conditions to be satisfied and the Offer is now unconditional in all respects.

Admission of the Enlarged Share Capital

Application has been made for the admission of the Consideration Shares and the Existing Ordinary Shares, being 445,622,374 Ordinary Shares to trading on AIM and Euronext Growth, which is expected to become effective and dealings commence at 8.00 a.m. on 20 January 2020.

Compulsory acquisition

Open Orphan intends to shortly exercise its rights pursuant to the provisions of sections 974-991 of the Companies Act to compulsorily acquire the remaining hVIVO Shares. The compulsory acquisition will be settled on the same terms as the Offer and hVIVO Shareholders will be entitled to receive 2.47 Open Orphan Shares for every 1 hVIVO Share.

In exercising such rights in respect of hVIVO Shares held by hVIVO Shareholders in, or with a registered address in, a Restricted Jurisdiction, Open Orphan may elect to arrange for such hVIVO Shares to be sold on behalf of the relevant hVIVO Shareholder and the proceeds (less the costs and expenses of such sale) remitted to such hVIVO Shareholder.

Enquiries:

 

Open Orphan plc

Cathal Friel, Chief Executive Officer

 

+353 (0)1 644 0007

Arden Partners plc (Nominated Adviser and Joint Broker)

John Llewellyn-Lloyd / Ben Cryer

 

+44 (0)20 7614 5900

JE Davy (Euronext Adviser and Joint Broker)

Anthony Farrell

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
OUPUNUARRRUAAUR
Date   Source Headline
29th Jan 20204:43 pmRNSHolding(s) in Company
28th Jan 20207:00 amRNSCompulsory Acquisition of Remaining hVIVO Shares
27th Jan 20203:00 pmRNSHolding(s) in Company
23rd Jan 20207:00 amRNSUpdate on Placing
22nd Jan 20209:58 amRNSHolding(s) in Company
22nd Jan 20209:48 amRNSHolding(s) in Company
21st Jan 20202:07 pmRNSHolding(s) in Company
20th Jan 20204:28 pmRNSHolding(s) in Company
20th Jan 20208:00 amRNSEuronext Growth Dublin Notice
20th Jan 20207:59 amRNSEuronext Growth Dublin Cancellation Notice
20th Jan 20207:00 amRNSCompletion of Merger with hVIVO and Re-Admission
17th Jan 20207:00 amRNSOffer Wholly Unconditional
16th Jan 20202:00 pmRNSSchedule One Update - Open Orphan PLC
16th Jan 20202:00 pmRNSSchedule One Update
15th Jan 20205:30 pmRNSOpen Orphan
14th Jan 202011:12 amGNWForm 8.3 - Open Orphan plc
14th Jan 20207:00 amRNSSecond Closing of the Offer
13th Jan 20209:00 amRNSPrice Monitoring Extension
7th Jan 20202:12 pmRNSPublication and Posting of Rule 15 Proposals
6th Jan 20201:17 pmRNSResult of General Meeting
6th Jan 20208:00 amRNSSchedule One - Open Orphan plc
6th Jan 20208:00 amRNSSchedule One
6th Jan 20207:00 amRNSNew 3 Year Contract
2nd Jan 202011:55 amRNSForm 8.5 (EPT/NON-RI)
2nd Jan 202011:44 amRNSForm 8.3 - Open Orphan PLC
31st Dec 201911:00 amRNSForm 8.5 (EPT/NON-RI)
31st Dec 20197:00 amRNSOffer Update
30th Dec 201910:00 amRNSForm 8.5 (EPT/NON-RI)
23rd Dec 201910:00 amRNSForm 8.5 (EPT/RI) - Open Orphan plc
23rd Dec 20199:30 amRNSForm 8.5 (EPT/NON-RI)
20th Dec 20195:39 pmRNSForm 8.3 - Open Orphan Plc
19th Dec 20194:39 pmRNSForm 8.3 - Open Orphan plc
19th Dec 20191:36 pmRNSForm 8.3 - Open Orphan plc
19th Dec 201911:55 amRNSForm 8.5 (EPT/NON-RI)
18th Dec 201912:05 pmRNSForm 8.5 (EPT/NON-RI)
18th Dec 20197:00 amRNSNew Contract with SFA Therapeutics
17th Dec 20194:38 pmRNSForm 8.3 - Open Orphan Plc
17th Dec 20194:36 pmRNSForm 8 (OPD)
17th Dec 20192:06 pmRNSForm 8.3 - Open Orphan PLC
17th Dec 20192:06 pmRNSForm 8.3 - Open Orphan PLC
17th Dec 20192:04 pmRNSForm 8.3 - Open Orphan PLC
17th Dec 20192:04 pmRNSForm 8.3 - Open Orphan PLC
17th Dec 201911:55 amRNSForm 8.5 (EPT/NON-RI)
17th Dec 201910:19 amRNSForm 8 (OPD)
17th Dec 201910:19 amRNSForm 8 (OPD) (hVIVO plc)
16th Dec 20192:02 pmRNSForm 8 (OPD) Open Orphan plc
16th Dec 201911:55 amRNSForm 8.5 (EPT/NON-RI)
16th Dec 201910:26 amRNSForm 8.5 (EPT/RI) - Open Orphan plc
13th Dec 201911:44 amRNSForm 8.3 - Open Orphan PLC
13th Dec 20197:00 amRNSForm 8.3 - Open Orphan plc

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.